Nuclera is moving into AI-enabled protein engineering, addressing a critical industry need for scalable, standardized, and high-quality datasets that can be used to power next-generation AI models. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
Cyborg Score Rationale
As of January 2026, Nuclera has raised $87 million in Series C funding, demonstrating investor confidence. The company's technology addresses a clear market need in accelerating protein access for drug discovery, and its pivot toward AI-enabled capabilities positions it at the intersection of biologics and artificial intelligence—two high-growth domains.
Top Insights
In January 2026, Nuclera extended Series C funding to $87M total, led by Elevage Medical Technologies and Jonathan Milner, enabling expanded antibody engineering and AI integration—critical for capturing the emerging AI-biologics datasets market.
Nuclera's benchtop platform uses cell-free synthesis, digital microfluidics, and software automation to enable miniaturized protein prototyping for challenging targets like membrane proteins, creating sticky customer relationships in academic and industrial drug discovery.
Nuclera was ranked among the fastest-growing UK/Ireland startups in 2024 and recognized as one of the UK's most exciting growth-stage technology companies by Tech Nation, signaling strong commercial traction and market validation.
Named Competitors
Synthego — Cell-free protein synthesis and CRISPR gene editing platform
Intrinsic Therapeutics — AI-driven protein design platform for drug discovery
Absci — Cloud-based AI protein design and optimization platform
Helixworks — Benchtop automation platform for protein engineering and expression
Recent Developments
(January 2026) Series C extension to $87M total for antibody engineering and AI-enabled protein engineering capabilities
(2024) Ranked among fastest-growing UK/Ireland startups
(2026) Commercial launch of protein prototyping technology at new headquarters (One Vision Park)
Open the full interactive Nuclera report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.